Aileron Therapeutics, Inc. (ALRN) financial statements (2021 and earlier)

Company profile

Business Address 290 PLEASANT STREET
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments14182151
Cash and cash equivalents751112
Short-term investments7131039
Restricted cash and investments1000
Other undisclosed current assets2111
Total current assets:16202252
Noncurrent Assets
Operating lease, right-of-use asset 6
Property, plant and equipment0070
Restricted cash and investments 11 
Other noncurrent assets  11
Total noncurrent assets:0791
TOTAL ASSETS:16263053
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3343
Accounts payable2122
Accrued liabilities0101
Employee-related liabilities1111
Debt 0  
Other undisclosed current liabilities1222
Total current liabilities:4655
Noncurrent Liabilities
Long-term debt and lease obligation 55 
Long-term debt, excluding current maturities  5 
Operating lease, liability 5
Other undisclosed noncurrent liabilities0   
Total noncurrent liabilities:055 
Total liabilities:410115
Stockholders' equity
Stockholders' equity attributable to parent12162048
Common stock0000
Additional paid in capital231214188185
Accumulated other comprehensive income (loss)(0)0(0)(0)
Accumulated deficit(219)(198)(168)(137)
Total stockholders' equity:12162048
TOTAL LIABILITIES AND EQUITY:16263053

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(20)(30)(32)(23)
Operating loss:(20)(30)(32)(23)
Nonoperating expense
(Other Nonoperating expense)
(1)   
Loss before gain (loss) on sale of properties:(21)(30)(32)(23)
Other undisclosed net income 10 
Net loss:(21)(29)(32)(23)
Other undisclosed net income attributable to parent   0
Net loss attributable to parent:(21)(29)(32)(23)
Preferred stock dividends and other adjustments   (0)
Net loss available to common stockholders, diluted:(21)(29)(32)(23)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(21)(29)(32)(23)
Comprehensive loss:(21)(29)(32)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)000
Comprehensive loss, net of tax, attributable to parent:(21)(29)(32)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: